Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Rheumatology Reports
Published in: Current Rheumatology Reports 5/2011

01-10-2011 | Clinical Trial Report

JAK Inhibition in Rheumatoid Arthritis

Authors: Aarat M. Patel, Daniel Lupash, Douglas Chew, Marc C. Levesque, Larry W. Moreland

Published in: Current Rheumatology Reports | Issue 5/2011

Login to get access

Excerpt

Trial: Kremer JM, Bloom BJ, Breedveld FC, et al.: The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 2009, 60(7):1895–1905. …
Literature
1.
Coombs JH, Bloom BJ, Breedveld FC, et al. Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2010;69:413–6.PubMedCrossRef
2.
Kremer JM, Cohen S, Wilkinson B, et al: Safety and efficacy after 24 weeks dosing of oral JAK inhibitor CP-690,550 in combination with methotrexate in patients with active rheumatoid arthritis. Arthritis Rheum 2009, 60(S719):1925 (abstract).
3.
Tanaka Y, Suzuki M, Nakamura H, et al: The oral JAK inhibitor CP-690,550 in combination with methotrexate is efficacious, safe and well tolerated in Japanese patients with active rheumatoid arthritis with an inadequate response to MTX alone. Abstract presented at the European League Against Rheumatism, Copenhagen, Denmark, June 10–13, 2009.
4.
Kanik K, Fleschmann RM, Cutolo M, et al: Phase 2B dose ranging monotherapy study of the oral JAK inhibitor CP-690,550 or adalimumab vs placebo in patients with active rheumatoid arthritis with an inadequate reponse to DMARDs. Ann Rheum Dis 2009, 68:123 OP-0159 (abstract).
5.
Riese RJ, Krishnaswami S, Kremer J. Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes. Best Pract Res Clin Rheumatol. 2010;24:513–26.PubMedCrossRef
Metadata
Title
JAK Inhibition in Rheumatoid Arthritis
Authors
Aarat M. Patel
Daniel Lupash
Douglas Chew
Marc C. Levesque
Larry W. Moreland
Publication date
01-10-2011
Publisher
Current Science Inc.
Published in
Current Rheumatology Reports / Issue 5/2011
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-011-0196-4

Other articles of this Issue 5/2011

Current Rheumatology Reports 5/2011 Go to the issue

ReviewPaper

The Natural Course of Radiographic Progression in Ankylosing Spondylitis: Differences Between Genders and Appearance of Characteristic Radiographic Features

ReviewPaper

Antibodies to Citrullinated Protein Antigens (ACPAs): Clinical and Pathophysiologic Significance

Clinical Trial Report

Cost-Effectiveness of Biologics Compared with Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis

ReviewPaper

Mucosal Inflammation in Spondylarthritides: Past, Present, and Future

ReviewPaper

Clinical Utility of the New ASAS Criteria for Spondyloarthritis and the Disease Activity Score

ReviewPaper

Familial Mediterranean Fever and Seronegative Arthritis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits